Marshall Edwards CEO to Present at JMP Securities Healthcare Conference in New York on September 27, 2010
Printer-friendly version
PDF versionAbout Marshall Edwards
Marshall Edwards, Inc. (NASDAQ: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from an investigational isoflavone technology platform that has generated a number of compounds with anti-proliferative tumor activity. These small molecules are believed to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. The Company's lead programs focus on two groups of compounds with related but distinct mechanisms of action. The first and most advanced is its NADH oxidase program, a family of compounds that includes Triphendiol and NV-143. The second is its novel mTORC1 and mTORC2 pathway inhibitor program, which includes NV-128 and NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.
Copy this html code to your website/blog and link to this press release.
More User Press Releases
- Marshall Edwards Reaches Agreement in Principle to Acquire Intellectual Property Portfolio from Novogen
- Marshall Edwards to Host Conference Call on September 8, 2010
- Marshall Edwards Appoints Oncologist Christine White to Board of Directors
- Marshall Edwards to present at the Rodman & Renshaw Conference
- Marshall Edwards achieves special protocol assessment and agreement with the FDA
- Marshall Edwards, Inc.,raises $10,000,000 in public offering
- Rodman & Renshaw presentation - 4 May 2005
- Phenoxodiol reverses chemo-resistance to docetaxel
- Corporate presentation made to the JPMorgan 25th Annual Healthcare Conference
- Interview with Marshall Edwards' CEO, Mr Christopher Naughton,
Facebook
Twitter
del.icio.us
LinkedIn
Digg
StumbleUpon
Forward
Google
Favorite
Favorite on Technorati